Spillover effects of HIV testing policies: Changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States

Jemima A. Frimpong, Thomas D'Aunno, Stéphane Helleringer, Lisa R. Metsch

Research output: Contribution to journalArticle

Abstract

Background: To examine the extent to which state adoption of the Centers for Disease Control and Prevention (CDC) 2006 revisions to adult and adolescent HIV testing guidelines is associated with availability of other important prevention and medical services. We hypothesized that in states where the pretest counseling requirement for HIV testing was dropped from state legislation, substance use disorder treatment programs would have higher availability of HCV testing services than in states that had maintained this requirement. Methods: We analyzed a nationally representative sample of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey (NDATSS). Data were collected from program directors and clinical supervisors through telephone surveys. Multivariate logistic regression models were used to measure associations between state adoption of CDC recommended guidelines for HIV pretest counseling and availability of HCV testing services. Results: The effects of HIV testing legislative changes on HCV testing practices varied by type of opioid treatment program. In states that had removed the requirement for HIV pretest counseling, buprenorphine-only programs were more likely to offer HCV testing to their patients. The positive spillover effect of HIV pretest counseling policies, however, did not extend to methadone programs and did not translate into increased availability of on-site HCV testing in either program type. Conclusions: Our findings highlight potential positive spillover effects of HIV testing policies on HCV testing practices. They also suggest that maximizing the benefits of HIV policies may require other initiatives, including resources and programmatic efforts that support systematic integration with other services and effective implementation.

Original languageEnglish (US)
Article number3322
JournalBMC Public Health
Volume16
Issue number1
DOIs
StatePublished - Jul 29 2016

Fingerprint

HIV
Guidelines
Pharmaceutical Preparations
Counseling
Therapeutics
Centers for Disease Control and Prevention (U.S.)
Opioid Analgesics
Substance-Related Disorders
Logistic Models
Buprenorphine
Methadone
Legislation
Telephone
Surveys and Questionnaires

Keywords

  • Buprenorphine
  • Centers for disease control and prevention
  • Drug treatment
  • HCV testing
  • HIV pretest counseling
  • HIV testing guidelines
  • HIV testing policies
  • Methadone
  • Programs

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Spillover effects of HIV testing policies : Changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States. / Frimpong, Jemima A.; D'Aunno, Thomas; Helleringer, Stéphane; Metsch, Lisa R.

In: BMC Public Health, Vol. 16, No. 1, 3322, 29.07.2016.

Research output: Contribution to journalArticle

@article{377d0c69909140259ee4151b490ef10f,
title = "Spillover effects of HIV testing policies: Changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States",
abstract = "Background: To examine the extent to which state adoption of the Centers for Disease Control and Prevention (CDC) 2006 revisions to adult and adolescent HIV testing guidelines is associated with availability of other important prevention and medical services. We hypothesized that in states where the pretest counseling requirement for HIV testing was dropped from state legislation, substance use disorder treatment programs would have higher availability of HCV testing services than in states that had maintained this requirement. Methods: We analyzed a nationally representative sample of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey (NDATSS). Data were collected from program directors and clinical supervisors through telephone surveys. Multivariate logistic regression models were used to measure associations between state adoption of CDC recommended guidelines for HIV pretest counseling and availability of HCV testing services. Results: The effects of HIV testing legislative changes on HCV testing practices varied by type of opioid treatment program. In states that had removed the requirement for HIV pretest counseling, buprenorphine-only programs were more likely to offer HCV testing to their patients. The positive spillover effect of HIV pretest counseling policies, however, did not extend to methadone programs and did not translate into increased availability of on-site HCV testing in either program type. Conclusions: Our findings highlight potential positive spillover effects of HIV testing policies on HCV testing practices. They also suggest that maximizing the benefits of HIV policies may require other initiatives, including resources and programmatic efforts that support systematic integration with other services and effective implementation.",
keywords = "Buprenorphine, Centers for disease control and prevention, Drug treatment, HCV testing, HIV pretest counseling, HIV testing guidelines, HIV testing policies, Methadone, Programs",
author = "Frimpong, {Jemima A.} and Thomas D'Aunno and St{\'e}phane Helleringer and Metsch, {Lisa R.}",
year = "2016",
month = "7",
day = "29",
doi = "10.1186/s12889-016-3322-4",
language = "English (US)",
volume = "16",
journal = "BMC Public Health",
issn = "1471-2458",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Spillover effects of HIV testing policies

T2 - Changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States

AU - Frimpong, Jemima A.

AU - D'Aunno, Thomas

AU - Helleringer, Stéphane

AU - Metsch, Lisa R.

PY - 2016/7/29

Y1 - 2016/7/29

N2 - Background: To examine the extent to which state adoption of the Centers for Disease Control and Prevention (CDC) 2006 revisions to adult and adolescent HIV testing guidelines is associated with availability of other important prevention and medical services. We hypothesized that in states where the pretest counseling requirement for HIV testing was dropped from state legislation, substance use disorder treatment programs would have higher availability of HCV testing services than in states that had maintained this requirement. Methods: We analyzed a nationally representative sample of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey (NDATSS). Data were collected from program directors and clinical supervisors through telephone surveys. Multivariate logistic regression models were used to measure associations between state adoption of CDC recommended guidelines for HIV pretest counseling and availability of HCV testing services. Results: The effects of HIV testing legislative changes on HCV testing practices varied by type of opioid treatment program. In states that had removed the requirement for HIV pretest counseling, buprenorphine-only programs were more likely to offer HCV testing to their patients. The positive spillover effect of HIV pretest counseling policies, however, did not extend to methadone programs and did not translate into increased availability of on-site HCV testing in either program type. Conclusions: Our findings highlight potential positive spillover effects of HIV testing policies on HCV testing practices. They also suggest that maximizing the benefits of HIV policies may require other initiatives, including resources and programmatic efforts that support systematic integration with other services and effective implementation.

AB - Background: To examine the extent to which state adoption of the Centers for Disease Control and Prevention (CDC) 2006 revisions to adult and adolescent HIV testing guidelines is associated with availability of other important prevention and medical services. We hypothesized that in states where the pretest counseling requirement for HIV testing was dropped from state legislation, substance use disorder treatment programs would have higher availability of HCV testing services than in states that had maintained this requirement. Methods: We analyzed a nationally representative sample of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey (NDATSS). Data were collected from program directors and clinical supervisors through telephone surveys. Multivariate logistic regression models were used to measure associations between state adoption of CDC recommended guidelines for HIV pretest counseling and availability of HCV testing services. Results: The effects of HIV testing legislative changes on HCV testing practices varied by type of opioid treatment program. In states that had removed the requirement for HIV pretest counseling, buprenorphine-only programs were more likely to offer HCV testing to their patients. The positive spillover effect of HIV pretest counseling policies, however, did not extend to methadone programs and did not translate into increased availability of on-site HCV testing in either program type. Conclusions: Our findings highlight potential positive spillover effects of HIV testing policies on HCV testing practices. They also suggest that maximizing the benefits of HIV policies may require other initiatives, including resources and programmatic efforts that support systematic integration with other services and effective implementation.

KW - Buprenorphine

KW - Centers for disease control and prevention

KW - Drug treatment

KW - HCV testing

KW - HIV pretest counseling

KW - HIV testing guidelines

KW - HIV testing policies

KW - Methadone

KW - Programs

UR - http://www.scopus.com/inward/record.url?scp=84979690341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979690341&partnerID=8YFLogxK

U2 - 10.1186/s12889-016-3322-4

DO - 10.1186/s12889-016-3322-4

M3 - Article

VL - 16

JO - BMC Public Health

JF - BMC Public Health

SN - 1471-2458

IS - 1

M1 - 3322

ER -